Projecting the United States ESRD population: Issues regarding treatment of patients with ESRD

Kidney International, Supplement

Volumn 66, Issue 90, 2004, Pages

  Szczech, Lynda Anne ^a   Lazar, Ira L ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Chronic kidney disease; End stage renal disease; Hemodialysis; Hypertension

Indexed keywords

COMORBIDITY; DIABETES MELLITUS; DIALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MEDICARE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; ADULT; AGED; CHRONIC KIDNEY FAILURE; ECONOMICS; MIDDLE AGED; UNITED STATES;

ADULT; AGED; HEALTH CARE COSTS; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; UNITED STATES;

EID: 4344652866     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.09002.x     Document Type: Review

References (46)

1. US RENAL DATA SYSTEM: USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institute of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 2003
2. FOLEY RN, PARFREY PS, SARNAK MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-119, 1998
3. US RENAL DATA SYSTEM: USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD National Institute of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 2002
4. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. New Engl J Med 342:1478-1483, 2000
5. KAYSEN GA: Hyperlipidemia of chronic renal failure. Blood Purif 12:60-67, 1996
6. BOSTOM AG, LATHROP L: Hyperhomocystinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 52:10-20, 1997
7. ATTMAN PO, SAMUELSSON O, ALAUPOVIC P, et al: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21:573-592, 1993
8. SECHI LA, ZINGARO L, DE CARLI S, et al: Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med 129:457-461, 1998
9. FLISER D, PACINI G, ENGELLEITER R, et al: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53:1343-1347, 1998
10. EIDEMAK I, FELDT-RASMUSSEN B, KANSTRUP IL, et al: Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia 38:565-572, 1995
11. KUTNER NG, CARDENAS DD, BOWER JD: Rehabilitation, aging and chronic renal disease. Am J Physical Med Rehab 71:97-101, 1992
12. SAGIV M, RUDOY J, ROTSTEIN A, et al: Exercise tolerance of end-stage renal disease patients. Nephron 57:424-427, 1991
13. LOWRIE EG, ZHU X, LEW NL: Primary associates of mortality among dialysis patients: Trends and reassessment of Kt/V and urea reduction ratio as outcome-based measures of dialysis dose. Am J Kidney Dis 32:516-31, 1998
14. SZCZECH LA, REDDAN DN, KLASSEN PS, et al: Interactions between dialysis-related volume exposures, nutritional surrogates, and mortality among ESRD patients. Nephrol Dial Transplant 18:1585-1591, 2003
15. OWEN WF, LEW NL, LIU Y, et al: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329:1001-1006, 1993
16. COLLINS AJ, MA JZ, UMEN A, KESHAVIAH P: Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 23:272-282, 1994
17. LOWRIE EG, LAIRD NM, PARKER TF, SARGENT JA: Effect of the hemodialysis prescription on patient morbidity. N Engl J Med 305:1176-1180, 1981
18. HAKIM RM, BREYER J, ISMAIL N, SCHULMAN G: Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 23:661-669, 1994
19. LOWRIE EG: Chronic dialysis treatment: Clinical outcome and related processes of care. Am J Kidney Dis 24:255-266, 1994
20. FERNANDEZ JM, CARBONELL ME, MAZZUCHI N, PETRUCCELLI D: Simultaneous analysis of morbidity and mortality factors in chronic hemodialysis patients. Kidney Int 41:1029-1034, 1992
21. HELD PJ, PORT FK, WOLFE RA, et al: The dose of hemodialysis and patient mortality. Kidney Int 50:550-556, 1996
22. PARKER T, HUSNI L, HUANG W, et al: Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis. Am J Kidney Dis 23:670-680, 1994
23. GOTCH F, LEVIN NW, PORT FK, et al: Clinical outcome relative to the dose of dialysis is not what you think: The fallacy of the mean. Am J Kidney Dis 30:1-15, 1997
24. OWEN WF, CHERTOW G, LAZARUS JM, LOWRIE EG: The dose of hemodialysis: Mortality responses by race and gender. JAMA 280:1-6, 1998
25. NATIONAL KIDNEY FOUNDATION: Dialysis Outcomes Quality Initiative Clinical Practice Guidelines. Accessed at www.kidney.org on June 7, 2004.
26. GUTHRIE M, CARDENAS D, ESCHBACH JW, et al: Effects of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol 39:97-102, 1993
27. WOLCOTT DL, MARSH JT, LA RUE A, et al: Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 14:478-485, 1989
28. WIZEMANN V, SCHAFER R, KRAMER W: Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 64:202-206, 1993
29. CANNELLA G, LA CANNA G, SANDRINI M, et al: Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol 34:272-278, 1990
30. MACDOUGALL IC, LEWIS NP, SAUNDERS MJ. et al: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335:489-493, 1990
31. PASCUAL J, TERUEL JL, MOYA JL, et al: Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol 35:280-287, 1991
32. FELLNER SK, LANG RM, NEUMANN A, et al: Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 44:1309-1315, 1993
33. LOW-FRIEDRICH I, GRUTZMACHER P, MARZ W, et al: Long-term echocardiographic examinations in chronic hemodialysis patients substituted with recombinant human erythropoietin. Blood Purif 8:272-278, 1990
34. SCHAEFER RM, KOKOT F, HEIDLAND A: Impact of recombinant erythropoietin on sexual function in hemodialysis patients. Contrib Nephrol 76:273-282, 1989
35. EVANS RW, RADER B, MANNINEN DL, COOPERATIVE MULTICENTER EPO CLINICAL TRIAL GROUP: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263:825-830, 1990
36. LOWRIE EG, LING J, LEW NL, YIU Y: The relative contribution of measured variables to death risk among hemodialysis patients, in Death on Hemodialysis: Preventable or Inevitable? edited by Friedman EA, Boston, MA. Kluwer Academic Publishers, 1994, pp 121-141
37. FOLEY RN, PARFREY PS, HARNETT JD, et al: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28:53-61, 1996
38. BESARAB A, BOLTON WK, BROWNE JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin. N Engl J Med 339:584-590, 1998
39. OWEN WF, JR, SZCZECH LA, FRANKENFIELD DL: Healthcare system interventions for inequality in quality: Corrective action through evidence-based medicine. J Nat Med Assoc 94:835-91S, 2002
40. SZCZECH LA, LOWRIE EG, LI Z, et al: Changing hemodialysis thresholds for optimal survival. Kidney Int 59:738-745, 2001
41. FOLEY RN, PARFREY PS, HARNETT JD, et al: Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 16:386-393, 1996
42. CAMPOS C, ARATA RO, MAUTALEN CA: Parathyroid hormone and vertebral osteosclerosis in uremic patients. Metabolism 25:495-501, 1976
43. FUSS M, DE BACKER M, BRAUMAN J, et al: Parathyroid hormone plasma level in untreated chronic renal failure and in hemodialyzed patients. Nephron 17:144-154, 1976
44. MALHOTRA KK, GADEKAR NG, UMASHANKAR P, BHARGAVA S: Bone disease in chronic renal failure. Indian J Med Res 56:1687-1695, 1968
45. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
46. HEALTHY PEOPLE 2010: available at http://www.healthypeople.gov/. Accessed June 7, 2004